The enforcement record on telehealth ADHD prescribing describes business-model features, and video is never the charge. Prosecutors and one admitted settlement point to capped visit lengths, pay tied to prescriptions, automatic refills with no clinical contact, prescribing-rate metrics, and non-clinicians approving clinical policy. As of September 2026 the federal telehealth rule underneath all of it ends December 31, 2026.
Stimulants are Schedule II, and the base rules are strict
Amphetamine, methylphenidate and lisdexamfetamine are federal Schedule II drugs. “The refilling of a prescription for a controlled substance listed in Schedule II is prohibited.” A prescriber may issue several prescriptions at once, for “a total of up to a 90-day supply,” but only if the prescriber “concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse.” The same rule says nothing in it encourages prescribers “to see their patients only once every 90 days.”
Every prescription also has to meet the oldest test in the regulations: “issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.” A clinician decides that, one patient at a time. A subscription cannot.
Telehealth adds the Ryan Haight in-person rule on top. A temporary regulation suspends it through December 31, 2026.
What prosecutors actually charged
The prosecution. In November 2025 a federal jury convicted the founder and the clinical president of a digital health company of conspiracy to distribute controlled substances, distribution, and conspiracy to commit health care fraud. They were sentenced in July 2026 to 72 months and 24 months. The Justice Department described the case as its first criminal drug distribution prosecutions related to a digital health company that distributed controlled substances by telemedicine. In its own words after sentencing, the investigation “reached beyond the individual clinicians writing the prescriptions to examine how corporate decisionmakers controlled its operations.”
The features the Department described, from its releases on the trial evidence:
- Initial visits limited to less than half the length of a typical psychiatric examination.
- Prescribers paid “solely based on the number of patients who received prescriptions,” with no pay for follow-up care.
- An “auto-refill” feature. Patients “could receive prescriptions without clinical interaction for years based on an auto-generated email sent each month.”
- Clinicians barred from discharging patients.
- A founder “who had no medical training” approving clinical practices, while the company claimed independent clinical leadership.
A separate indictment of the company and an affiliated medical practice, returned in December 2025, is pending. Its claims are allegations. One of them is that an entity was created to get around pharmacies that had blocked the platform’s prescriptions.
The settlement. A second telehealth company resolved a federal investigation in November 2024 through a non-prosecution agreement. It admitted a statement of facts as “potential violations of law, specifically attempted distribution of controlled substances.” The facts included a tracked rate of prescribing at the first visit, with “flags” and “strikes” considered for clinicians who underperformed on it. They also included “thousands of duplicate patient accounts” left unaddressed for a period. The company stopped prescribing controlled substances in October 2022 and agreed not to resume.
Pharmacies are the second checkpoint
The same regulation that binds the prescriber says “a corresponding responsibility rests with the pharmacist who fills the prescription.” DEA’s manual for pharmacists adds that the law “does not require a pharmacist to dispense a prescription of doubtful, questionable, or suspicious medical legitimacy.” According to the Justice Department, national pharmacy chains blocked one platform’s prescriptions. If pharmacies near your patients refuse your prescriptions, read that as a warning about your model.
State rules bind you whatever DEA does in December
| State | Rule | Effect on a telehealth ADHD program |
|---|---|---|
| Florida | § 456.47(2)(c) | No Schedule II by telehealth except for listed uses. “The treatment of a psychiatric disorder” is one. Chart the diagnosis. |
| West Virginia | § 30-3-13a(g) | No Schedule II for a patient seen solely by telemedicine. Exceptions for established patients and for minors and certain students. Most adults are barred. |
| Ohio | OAC 4731-11-09 | In-person visit before Schedule II for a new patient, except where the drug treats a mental health condition. |
| Alabama | § 34-24-704(b) | An in-person encounter within the preceding 12 months for any controlled substance. |
| New Hampshire | RSA 329:1-d, III | A follow-up evaluation “not less than annually.” |
| Kentucky | 201 KAR 9:016; KRS 218A.172 | The record must show the diagnosis that justifies a Schedule II stimulant. History, examination, PDMP query, written plan and consent before the first prescription. |
| New York | 10 NYCRR 80.63 | In-person evaluation required, with a telehealth exception tied to DEA’s rules. It moves when the federal rule moves. |
| Georgia | Rule 360-3-.02(5) | Prescribing a controlled substance “based solely on a consultation via electronic means” is unprofessional conduct. The rule has a narrow ADHD carve-out that still depends on the federal in-person statute. |
We verified these eight. Other states have rules we could not confirm from a primary source, including Indiana, Louisiana, Tennessee and Washington.
Nurse practitioner authority is the quiet constraint
Many telehealth ADHD programs are staffed by nurse practitioners. State law decides whether an NP may prescribe a Schedule II stimulant at all.
- Texas. A physician may delegate Schedule II prescribing only in hospital facility-based practice and hospice. There is no outpatient ADHD route for NPs or PAs.
- Missouri. Delegable authority covers Schedules III through V and Schedule II hydrocodone. Stimulants are outside it.
- Georgia. The medical board’s June 2024 notice says the new Schedule II authority covers hydrocodone and oxycodone in emergencies. We did not check for later changes.
- Florida. Schedule II is limited to “a 7-day supply,” except psychiatric medications prescribed by a psychiatric nurse as the statute defines one.
NP versus physician covers the broader trade-off. For stimulants, check the prescriber’s authority state by state before you market there.
The criminal standard, and what it means for your charts
In Ruan v. United States (2022), the Supreme Court held that once a defendant shows authorization to dispense, the government must prove the defendant “knew that he or she was acting in an unauthorized manner, or intended to do so.” That protects a clinician who exercises and documents real judgment. It does little for a company whose own records show prescribing targets.
Five features of a defensible program
- Clinicians set visit length and may discharge any patient. No non-clinician can override either.
- Compensation is never tied to prescriptions or prescribing rates, and follow-up visits are paid.
- No automatic refills. A clinician assessment sits behind every Schedule II prescription, and any multi-prescription supply meets the conditions in 21 C.F.R. § 1306.12(b).
- A PDMP check on every new start and on a schedule after that, duplicate-account controls, and no reassignment of patients who were declined. California requires a check before the first prescription and at least every six months.
- Ongoing monitoring for misuse, and non-stimulant options that are actually offered. FDA’s 2023 communication tells prescribers to watch for “more frequent renewal requests than warranted by the prescribed dosage.”
These are clinical standards questions before they are legal ones. In our structure the professional entity sets them and the brand does not.
What this means for you
If you run or fund an online brand in this category, audit your own documents first: compensation plans, dashboards, growth targets and refill logic. Those are what the government quoted. Then map each state you sell into against the table above and against your prescribers’ licenses. Finally, plan for December 31, 2026. The DEA’s January 2025 proposal would have limited telehealth Schedule II prescribing to listed specializts located in the patient’s state. The final text is not public.
Related reading
Frequently asked questions
Can you prescribe Adderall through telehealth?
As of September 2026, federal law allows it without an in-person evaluation under a temporary rule, 21 C.F.R. § 1307.41, which expires December 31, 2026. State law may be stricter. West Virginia bars it for most adults seen only by telemedicine, Alabama requires an in-person encounter within 12 months, and Florida allows it only for listed uses such as psychiatric disorders.
Can a nurse practitioner prescribe ADHD stimulants by telehealth?
It depends on the state. Texas allows delegated Schedule II prescribing only in hospital and hospice settings. Missouri’s delegable authority does not include stimulants. Florida limits most nurse practitioners to a seven-day Schedule II supply unless they qualify as psychiatric nurses. Check the authority in every state where the patient sits.
What did telehealth ADHD companies get prosecuted for?
The Justice Department’s releases describe capped initial visits, prescriber pay based only on patients who received prescriptions, no pay for follow-up, automatic monthly refills with no clinical contact, a ban on discharging patients, and a founder with no medical training approving clinical practices. Using video was never the charge.
Are Schedule II refills allowed by telehealth?
No Schedule II prescription may be refilled, by telehealth or in person. A prescriber may issue multiple prescriptions covering up to a 90-day supply if five conditions are met, including a conclusion that doing so creates no undue risk of diversion or abuse. Automatic monthly renewals without a clinician’s assessment do not meet that rule.
Will telehealth stimulant prescribing be legal in 2027?
Nobody outside the government knows yet. The temporary federal rule ends December 31, 2026. A final special registration rule has been under White House review since August 25, 2026, and its text is not public. The January 2025 proposal would have limited Schedule II telehealth prescribing to listed specializts in the patient’s state.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.